Silence Therapeutics plc ADR (SLN)
SLN Stock Skyrockets 107% in Six Months: Here's What You Need to Know
Silence Therapeutics shares surge as investors eye key 2026 divesiran data, an advancing RNAi pipeline and progress across multiple siRNA programs.
Silence Therapeutics (SLN) Moves 7.2% Higher: Will This Strength Last?
Silence Therapeutics (SLN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Silence Therapeutics: PV Data Could Wake The Stock (Initiating Buy)
I initiate Silence Therapeutics at a speculative Buy, driven by near-term divesiran/SLN124 catalysts in polycythemia vera (PV). SLN's mRNAi GOLD GalNAc-siRNA platform enables infrequent dosing and strong target knockdown, potentially differentiating divesiran from weekly competitors like Rusfertide. Phase 1 SANRECO data show promising phlebotomy reduction and symptom improvement, but safety and efficacy require confirmation in the pivotal Phase 2 readout (August 2026).
Silence Therapeutics (SLN) Surges 26.0%: Is This an Indication of Further Gains?
Silence Therapeutics (SLN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Silence Therapeutics (SLN) Soars 19.0%: Is Further Upside Left in the Stock?
Silence Therapeutics (SLN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Wall Street Analysts See a 467.47% Upside in Silence Therapeutics (SLN): Can the Stock Really Move This High?
The consensus price target hints at a 467.5% upside potential for Silence Therapeutics (SLN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Silence Therapeutics: Divesiran Targets High-Burden PV
Silence Therapeutics is advancing its lead RNAi drug, divesiran, for polycythemia vera, with a fully enrolled Phase 2 trial and results expected in Q3 2026. SLN boasts a strong cash position ($100M+), providing runway through 2028 and enabling continued pipeline development without near-term financing risks. The SANRECO trial's design and patient population position divesiran as a potential adjunctive therapy for high-burden PV patients, focusing on reduced phlebotomy frequency and infrequent dosing.
Wall Street Analysts Think Silence Therapeutics (SLN) Could Surge 556.19%: Read This Before Placing a Bet
The consensus price target hints at a 556.2% upside potential for Silence Therapeutics (SLN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Silence Therapeutics (SLN) Upgraded to Buy: Here's What You Should Know
Silence Therapeutics (SLN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Silence Therapeutics plc (SLN) Q4 2024 Earnings Call Transcript
Silence Therapeutics plc (NASDAQ:SLN ) Q4 2024 Earnings Call February 27, 2025 8:00 AM ET Company Participants Gem Hopkins - Vice President, Investor Relations and Corporate Communications Craig Tooman - President and Chief Executive Officer Rhonda Hellums - Chief Financial Officer Steven Romano - Chief R&D Officer Conference Call Participants Mike Ulz - Morgan Stanley Kostas Biliouris - BMO Capital Markets Richard Law - Goldman Sachs Keay Nakae - Chardan Myles Minter - William Blair Gem Hopkins Good morning and good afternoon, everyone. Thank you for joining us today.
SLN Stock Down Despite Cholesterol Drug Lowering Lipoprotein Levels
Silence Therapeutics stock falls despite lowering lipoprotein levels in a phase II study of zerlasiran likely due to concerns regarding its competitive profile.
Silence Therapeutics' Zerlasiran Has Competitive Concerns: Analyst
On Monday, Silence Therapeutics plc SLN presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran in atherosclerotic cardiovascular disease (ASCVD) patients with high lipoprotein(a) [Lp(a)] levels (≥125 nmol/L).
